
Claims

1. A combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof:



I

2. The combination according to claim 1, wherein the pharmaceutically acceptable salt of the compound of formula I is the hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, tosylate, salicylate, lactate, naphthalenesulfonate or acetate salt.

3. The combination according to claim 1 or claim 2, wherein the proteasome inhibitor is selected from the group consisting of bortezomib, carfilzomib, marizomib, delanzomib (CEP-18770), oprozomib (ONX 0912), ixazomib (MLN-9708) and LU-102, or a pharmaceutically acceptable salt thereof.

4. The combination according to claim 1 or claim 2, wherein the proteasome inhibitor is selected from bortezomib, carfilzomib and LU-102.

5. The combination according to any one of claims 1 to 4, further comprising a glucocorticoid.

6. The combination according to claim 5, wherein the glucocorticoid is selected from the group consisting of dexamethasone, fluocinolone acetonide and prednisone.

7. The combination according to claim 5, wherein the glucocorticoid is dexamethasone.

8. The combination according to any one of claims 1 to 7, wherein the molar ratio of proteasome inhibitor to compound of formula I or a pharmaceutically acceptable salt thereof in said combination is from 1:1000 to 1000:1, from 1:1000 to 10:1, or from 1:5 to 1:0.5.

9. The combination according to any one of claims 1 to 8, further comprising a glucocorticoid wherein the molar ratio of proteasome inhibitor to the compound of formula I or a pharmaceutically acceptable salt thereof to the glucocorticoid in said combination is from 1:1000:10 to 1000:1:20, or from 1:3:4 to 1:0.5:3.

10. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a combination according to any one of claims 1 to 9.

11. A kit comprising a combination according to any one of claims 1 to 9, and optionally, instructions for treating a patient.

12. The use of the combination according to any one of claims 1 to 9, the composition according to claim 10 or the kit according to claim 11 in the manufacture of a medicament for the treatment of cancer.

13. The use of a combination, composition or kit according to claim 12, wherein said cancer is selected from a hematologic cancer and breast cancer.

14. The use of a combination, composition or kit according to claim 13, wherein said hematologic cancer is selected from multiple myeloma, lymphoma and leukemia.

15. The use of a combination, composition or kit according to claim 13, wherein said breast cancer is a triple-negative breast cancer.

16. The use of a combination, composition or kit according to any one of claims 12 to 15, wherein the cancer is relapsed and/or refractory.


17. The use of a combination, composition or kit according to any one of claims 12 to 16, wherein in said treatment the proteasome inhibitor, the compound of formula I or a pharmaceutically acceptable salt thereof and, if present, the glucocorticoid are to be administered concurrently, sequentially or separately.

18. The use of a combination, composition or kit according to any one of claims 12 to 17, wherein in said treatment the proteasome inhibitor is to be administered to the patient at a

dosage range of 0.01 to 0.3 mg/kg body weight patient, preferably at a dosage range of 0.05 to 0.15 mg/kg body weight patient.

19. The use of a combination, composition or kit according to any one of claims 12 to 18, wherein the glucocorticoid, if present, is to be administered at a dosage range of from 0.1 to 1 mg/kg body weight patient, preferably at a dosage range of from 0.3 to 0.5 mg/kg body weight patient.


20. The use of a compound of formula I or a pharmaceutically acceptable salt thereof:



I,

in the manufacture of a medicament for the treatment of cancer, wherein the compound of formula I or a pharmaceutically acceptable salt thereof is to be administered in combination with a proteasome inhibitor.


21. The use of a proteasome inhibitor in the manufacture of a medicament for the treatment of cancer, wherein the proteasome inhibitor is to be administered in combination with a compound of formula I or a pharmaceutically acceptable salt thereof:



I.

22. The use of the compound of formula I or a pharmaceutically acceptable salt thereof according to claim 20 or the use of a proteasome inhibitor according to claim 21, wherein the compound of formula I or a pharmaceutically acceptable salt thereof or proteasome inhibitor are to be administered in combination with ~~further comprising administration of~~ a glucocorticoid.

23. The use of a compound of formula I or a pharmaceutically acceptable salt thereof:



I

in the manufacture of a medicament for the treatment of multiple myeloma, wherein the multiple myeloma is relapsed and/or refractory.